Stemedica Cell Technologies announced the launch of a phase 2b/3 clinical trial to assess the safety, efficacy and tolerability of a single IV injection of allogenic mesenchymal stem cells in patients with chronic ischemic stroke.
According to a release from the company, the multicenter, randomized, double-blind study is expected to enroll approximately 300 individuals, who will be divided into two cohorts and receive either a single injection of allogeneic mesenchymal stem cells and standard treatment or placebo and standard treatment.
The study will assess improvements in clinical outcomes of